<DOC>
	<DOCNO>NCT00386802</DOCNO>
	<brief_summary>Primary purpose : Frequency use broad-spectrum antifungal episode neutropenia . Secondary purpose : To determine safety toxicity measure : 1 . Frequency Invader Fungal Infection . 2 . Frequency global use broad-spectrum antifungal amphotericine , itraconazole , voriconazole , caspofungin , terbinafine , period study . 3 . Mortality 4 . Development nephrotoxicity 5 . Use galactomannan clinical context 6 . Time administration empirical antifungal therapy broad-spectrum .</brief_summary>
	<brief_title>Antifungal Use Oncohematological Neutropenic Patients</brief_title>
	<detailed_description>Clinical trial pharmaceutical speciality condition authorize use</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Adult pediatric patient ( 2 year old ) diagnostic hematologic malignancy solid tumour . Patients develop neutropenia ( &lt; 500PN ) post chemotherapy post Bone Marrow Transplantation ( BMT ) accord center , receive empirical antifungal treatment broadspectrum . Controlled patient galactomannan blood twice weekly . Empirical antibacterial therapy broadspectrum , possible Pethema protocol activate moment . Also validate monotherapy carbapenemic cephalosporin fourth third generation , biotherapy . Inclusion patient since start chemotherapy therapy preparation . If bacterial infection document , treat control begin empirical antifungal treatment . Signed informed consent . Negative pregnancy test fertile patient Use antifungal prophylaxis triazoles activity Aspergillus , use others systematics antifungal previous Invader Fungal Infection reason . Use prophylactic fluconazole dose high 100 mg/day . Allergy azoles To invader fungal infection start episode neutropenia fever . High effect unity insulation Candida strong fluconazole opinion center hasn´t appropriate include protocol consider use empirical fluconazole . Neutropenias make aplastic anemia fault bone similar . Inclusion previous study . The patient exclude settled Aspergillus , C.krusei C.gladiata episode neutropenia , lack result culture vigilance present episode . If present positive result pathogens empirical treatment must antifungal cover good ( amphotericin , caspofungin voriconazole ) fluconazole , patient follow protocol . To receive drug , aren´t indicated patient treatment voriconazole and/or fluconazole . The patient exclude receive antibacterial prophylaxis oral quinolones , macrolides , etc. , stimulate factor GCSF , GMCSF similar . Cause exclusion fault fulfilment inclusion criterion . Above patient exclude : fault twice weekly monitoring galactomannan . bacterial infection good treat controlled begin empirical antifungal infection ( accord definition previous ) final , neutropenia short stay risk important Invader Fungal Infection . This data naturally know moment include patient study . It define neutropenia short stay last less 5 day .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Antifungals</keyword>
</DOC>